Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
A phase 2 clinical trial of the diabetes drug pioglitazone in ALS was terminated after it failed to reach its primary endpoint of increased survival time
Posted on Tuesday, June 19, 2012 - 03:05, By: Other
The anti-diabetic drug pioglitazone did not improve survival time when tested as an add-on therapy to riluzole in a phase 2 clinical trial of people with amyotrophic lateral sclerosis (ALS).
The trial, which was conducted in Germany, was stopped early "for futility" when interim results showed no...
ALS TDI’s 2011 Leadership Summit included the latest on ALS research and a discussion of speeding the pace of drug development
Posted on Wednesday, November 16, 2011 - 09:57, By: Amy Madsen
ALS experts talked about the state of research, and industry leaders discussed ways to improve the pace and efficiency of ALS drug development at the 2011 ALS TDI Leadership Summit, Nov. 4, 2011. The Summit, an annual conference hosted by the MDA-supported ALS Therapy Development Institute (ALS TDI...
Motor neurons are lost in ALS, but new evidence shows they don't die without significant help from their neighboring cells. These neighbors may be easier to target with therapies than the motor neurons themselves.
Posted on Saturday, May 1, 2010 - 10:04, By: Margaret Wahl
An ALS Therapy Development Institute Webcast summarizes research progress as of July 2009
Posted on Wednesday, July 29, 2009 - 10:38, By: Amy Madsen
On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who register. (See Research Update Q209.)